Dyne Therapeutics Inc (NASDAQ: DYN) is -40.92% lower on its value in year-to-date trading and has touched a low of $13.23 and a high of $47.45 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DYN stock was last observed hovering at around $13.52 in the last trading session, with the day’s gains setting it 0.4%.
Currently trading at $13.92, the stock is -3.31% and -32.74% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.46 million and changing 2.96% at the moment leaves the stock -55.34% off its SMA200. DYN registered -42.02% loss for a year compared to 6-month loss of -67.68%. The firm has a 50-day simple moving average (SMA 50) of $21.0386 and a 200-day simple moving average (SMA200) of $31.216776.
The stock witnessed a -8.96% gain in the last 1 month and extending the period to 3 months gives it a -51.12%, and is -11.22% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.84% over the week and 7.09% over the month.
Dyne Therapeutics Inc (DYN) has around 141 employees, a market worth around $1.42B and $0.00M in sales. Distance from 52-week low is 5.18% and -70.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-40.59%).
The EPS is expected to grow by 12.26% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
The shares outstanding are 101.75M, and float is at 76.64M with Short Float at 12.47%.
The top institutional shareholder in the company is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with over 8.02 million shares valued at $283.03 million. The investor’s holdings represent 9.8961 of the DYN Shares outstanding. As of 2024-06-30, the second largest holder is FCPM III SERVICES B.V. with 7.85 million shares valued at $276.86 million to account for 9.6804 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.39 million shares representing 9.1148 and valued at over $260.69 million, while RTW INVESTMENTS, LP holds 7.8811 of the shares totaling 6.39 million with a market value of $225.4 million.
Dyne Therapeutics Inc (DYN) Insider Activity
The most recent transaction is an insider sale by Beskrovnaya Oxana, the company’s Chief Scientific Officer. SEC filings show that Beskrovnaya Oxana sold 2,334 shares of the company’s common stock on Dec 11 ’24 at a price of $28.12 per share for a total of $65632.0. Following the sale, the insider now owns 0.2 million shares.
Dyne Therapeutics Inc disclosed in a document filed with the SEC on Dec 11 ’24 that Scalzo Richard William (SVP, Head of Finance & Admin.) sold a total of 1,455 shares of the company’s common stock. The trade occurred on Dec 11 ’24 and was made at $28.12 per share for $40915.0. Following the transaction, the insider now directly holds 0.13 million shares of the DYN stock.
Still, SEC filings show that on Dec 11 ’24, HIGH SUSANNA GATTI (Officer) Proposed Sale 5,270 shares at an average price of $28.33 for $0.15 million. The insider now directly holds shares of Dyne Therapeutics Inc (DYN).
